News

Material Fact

CENTRO DE IMAGEM DIAGNÓSTICOS S.A. ("Company" or "Alliar"), in compliance with paragraph 4 of article 157 of Law 6404/76 and Instruction 358/02 of the Brazilian Securities and Exchange Commission ("CVM"), hereby informs its shareholders and the market in general that it will upstream integrate its Clinical Analysis operation, through the construction of its own central laboratory (NTO).

To lead the project, the Company announces the hiring of Ricardo Dupin, MD to occupy the position of Director of Laboratory Medicine. The election of Ricardo Dupin, MD will be submitted to the Company‘s Board of Directors. The Company will inform the market when the election and investiture of Ricardo Dupin, MD takes place.

Ricardo Dupin has 19 years of experience in the health sector, and has served as an executive at Pardini, DASA and São Marcos. He has solid experience in expansion projects, creation of B2B channels, M & A and implementation of operational technical centers. He holds a degree in medicine from the Faculty of Medical Sciences of Belo Horizonte / MG, MD Residency in Internal Medicine HGIP, Belo Horizonte / MG and an MBA from IBMEC Business School, Belo Horizonte / MG.

In this context, the Company informs that, on May 10 of this year, it sent the termination notification of the supply contract with AFIP - ASSOCIAÇÃO FUNDO DE INCENTIVO A PESQUISA. The contract must end within 12 (twelve) months from the date of notification, when the Parties will formalize the Term of Termination and Settlement.

São Paulo, May 13, 2021

For more information, access our IR website.

IR Contact

Gabriel Bouzada Rozenberg
Investor Relations Officer
E-mail:
ri@alliar.com